The European Union approves a more efficient dosage of semaglutide injection for the treatment of adult obesity.

Gelonghui, February 27th - Novo Nordisk announced that the European Commission has approved a new 7.2 mg once-weekly maintenance dose of semaglutide injection for adult patients with obesity. This approval means that doctors in the EU can now prescribe the 7.2 mg dose, which is administered as a single injection of three 2.4 mg pens, still as a once-weekly injection. Novo Nordisk has submitted a marketing authorization application for a 7.2 mg single-dose injection pen to the EU, and if approved, it is expected to be launched this year. Previously, the 7.2 mg semaglutide injection has been approved and launched in the UK. In addition, the US Food and Drug Administration (FDA) and regulatory agencies in several other countries are reviewing its registration application.